Goldman Sachs Maintains Buy on Calumet Specialty Prods, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Neil Mehta maintains a Buy rating on Calumet Specialty Prods (NASDAQ:CLMT) and lowers the price target from $20 to $19.
June 13, 2023 | 12:29 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Calumet Specialty Prods (NASDAQ:CLMT) and lowers the price target from $20 to $19.
Goldman Sachs' lowered price target on CLMT may cause short-term uncertainty among investors, but the maintained Buy rating indicates a positive outlook for the stock. The impact on the stock price is expected to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100